World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
24925
World Ranking
13281
National Ranking
6761

John J. Wright publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John J. Wright sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 353 publications — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John J. Wright D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John J. Wright sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John J. Wright is affiliated with the National Institutes of Health in the United States. Their research primarily focuses on areas within biochemistry, genetics, and molecular biology, with significant contributions in medicine. The scientist's work spans several subfields, including molecular biology, oncology, biophysics, renewable energy, sustainability and the environment, and pulmonary and respiratory medicine.

The main topics addressed in their research include photosynthetic processes and mechanisms, ATP synthase and ATPases research, mitochondrial function and pathology, electron spin resonance studies, lipid membrane structure and behavior, metalloenzymes and iron-sulfur proteins, and acute myeloid leukemia research.

John J. Wright has published extensively in a variety of academic venues. The most frequent publication outlets are:

  • Nature Communications
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood
  • Chemistry - A European Journal
  • Current Opinion in Structural Biology

Their recent papers include:

  • Structure of inhibitor-bound mammalian complex I, 2020, Nature Communications
  • Cryo-EM structures define ubiquinone-10 binding to mitochondrial complex I and conformational transitions accompanying Q-site occupancy, 2022, Nature Communications
  • Functional basis of electron transport within photosynthetic complex I, 2021, Nature Communications
  • Making the leap from structure to mechanism: are the open states of mammalian complex I identified by cryoEM resting states or catalytic intermediates?, 2022, Current Opinion in Structural Biology
  • Reverse Electron Transfer by Respiratory Complex I Catalyzed in a Modular Proteoliposome System, 2022, Journal of the American Chemical Society

This scientist has collaborated frequently with several researchers, demonstrating a pattern of ongoing scientific partnerships. Frequent co-authors include:

  • Judy Hirst
  • Maxie M. Roessler
  • Daniel N. Grba
  • Hannah R. Bridges
  • Injae Chung

Best Publications

  • Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Richard L. Piekarz;Robin Frye;Maria Turner;John J. Wright

  • Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

    Owen A. O'Connor;John Wright;Craig Moskowitz;Jamie Muzzy

  • Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

    Richard T. Kloos;Matthew D. Ringel;Michael V. Knopp;Nathan C. Hall

  • Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

    Judith E. Karp;Jeffrey E. Lancet;Scott H. Kaufmann;David W. End

  • Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

    Richard L. Piekarz;Robin Frye;H. Miles Prince;Mark H. Kirschbaum

  • A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

    John C. Byrd;Guido Marcucci;Mark R. Parthun;Jim J. Xiao

  • Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

    William L. Dahut;James L. Gulley;Philip M. Arlen;Yinong Liu

  • Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

    Elaine T. Lam;Matthew D. Ringel;Richard T. Kloos;Thomas W. Prior

  • Sorafenib for Advanced and Refractory Desmoid Tumors.

    Mrinal M. Gounder;Michelle R. Mahoney;Brian A. Van Tine;Vinod Ravi

  • Clinical Toxicities of Histone Deacetylase Inhibitors.

    Srividya Subramanian;Susan E. Bates;John J. Wright;Igor Espinoza-Delgado

  • Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

    Nilofer S. Azad;Edwin M. Posadas;Virginia E. Kwitkowski;Seth M. Steinberg

  • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

    Ravi A Madan;Mahsa Mohebtash;Philip M Arlen;Matteo Vergati

  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

    James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang

  • Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

    Shivanni Kummar;Helen X. Chen;John Wright;Susan Holbeck

  • Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

    Ashraf Badros;Angelika M. Burger;Sunita Philip;Ruben Niesvizky

  • Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer

    Alex A. Adjei;Ann Mauer;Laura Bruzek;Randolph S. Marks

  • Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.

    Richard L. Piekarz;A. Robin Frye;John J. Wright;Seth M. Steinberg

  • A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer

    Geoffrey I. Shapiro;Jeffrey G. Supko;Angus Patterson;Cathy Lynch

  • Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

    Gautam Borthakur;Hagop Kantarjian;Farhad Ravandi;Weiguo Zhang

  • Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

    Melissa Alsina;Rafael Fonseca;Edward F. Wilson;A. Nelida Belle

Frequent Co-Authors

William D. Figg
William D. Figg National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
James L. Gulley
James L. Gulley National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
Judith E. Karp
Judith E. Karp Johns Hopkins University
Joseph A. Sparano
Joseph A. Sparano Albert Einstein College of Medicine
B. Douglas Smith
B. Douglas Smith Johns Hopkins University
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
Jorge E. Cortes
Jorge E. Cortes Augusta University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical education in the USA can open doors to a variety of healthcare career options, especially with the growth of accessible online degree programs. Many students and working professionals are seeking cost-effective solutions, such as the cheapest bsn programs online, which allow for flexible learning while minimizing debt.

For registered nurses aiming to expand their qualifications, knowing what is the cheapest rn to bsn program online is crucial. These bridge programs are designed to be completed quickly and affordably, helping nurses advance their roles within the healthcare system.

Those pursuing leadership, advanced research, or academic careers may consider online phd nursing programs. Such degrees provide flexibility and specialized knowledge for high-level positions.

Additionally, career changers with non-nursing backgrounds can enter the profession through online msn programs for non nurses. These pathways offer direct progression into master’s-level nursing, preparing graduates for advanced practice or management roles.

Exploring these online pathways ensures you find the right fit—both academically and financially—on the road to a rewarding healthcare career.

Best Scientists Citing John J. Wright

Trending Scientists

Recently Published Articles